Skip to content

Evaluation of Quickly Diagnostic Saliva Tests for SARS-CoV-2

Evaluation of Quickly Diagnostic Saliva Tests for SARS-CoV-2

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04337424
Acronym
EasyCoV
Enrollment
627
Registered
2020-04-07
Start date
2020-04-13
Completion date
2020-10-07
Last updated
2026-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

SARS-CoV-2

Keywords

Diagnosis test, Salivary sampling

Brief summary

Coronavirus disease 2019 or COVID-19 is a highly contagious infectious disease. Symptoms of the disease are non-specific (fever, cough, dyspnea and fatigue), common with many seasonal viruses, which complicates the diagnosis. For mild forms, which represent the vast majority of cases, hospitalization is not necessary and treatment is symptomatic. However in more severe cases, hospitalization is required and sometimes even admission to an intensive care unit. Several diagnostic tests are already available, but they require, in all cases, the intervention of qualified health personnel to carry out the sample, which includes a risk of contagion and an expensive and time-consuming laboratory analysis and reagents. These tests are therefore not very suitable for massive screenings. We want to evaluate the performance of a detection test performed on a salivary sample in the diagnosis of SARS-CoV-2. This test will be non-invasive, performed without any analytical device and will restore its qualitative result "infected versus non-infected" in less than 1 hour (30min objective).

Detailed description

Study taking place at the Montpellier University Hospital, comparing a salivary sample group with active infection (participants) for SARS-COV2 with a salavary sample tested negative (cured, convalescent and negative) for SARS-COV2 (healthcare workers ,participants)

Interventions

DIAGNOSTIC_TESTSampling salivary

Collection of 1 to 2 ml of saliva

Sponsors

University Hospital, Montpellier
Lead SponsorOTHER
societe SkillCell - 97198 Jarry
CollaboratorUNKNOWN
CNRS Alcediag UMR9005 - societe Sys2Diag - 34184 Montpellier
CollaboratorUNKNOWN

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
Yes

Inclusion criteria

\- Control subjects (COV2- group): Participants ( Healthcare staff, patients and DRIVE participants) negative for SARS-CoV-2 \- Infected subjects (COV2 + group): Patients diagnosed positive for SARS-CoV-2 hospital staff known to be positive and coming to do a control PCR DRIVE participants.

Exclusion criteria

* Eligibility Criteria: Inclusion Criteria: \- Control subjects (COV2- group): Healthcare staff presumed and diagnosed negative for SARS-CoV-2 \- Infected subjects (COV2 + group): Patients diagnosed positive for SARS-CoV-2 hospital staff known to be positive and coming to do a control PCR

Design outcomes

Primary

MeasureTime frameDescription
Specific detection of SARS-CoV-2 specific RNA1 dayDetection by the LAMP method is to be corroborated with the reference method, RT-PCR on the same salivary sample. Only one sample is taken per subject participating in the study. The sample is divided into two aliquots which will be analyzed by LAMP and RT-PCR

Secondary

MeasureTime frameDescription
Analytical sensitivity of the LAMP test.1 dayThis test developed by SYS2DIAG / SKILLCELL must be able to detect a minimum viral load equivalent to that of the standard method on the same salivary sample.
The correlation between the measurement of the assayed viral load (CT value) by the standard method and by the LAMP developed by SYS2DIAG / SKILLCELL.1 dayA correlation between the viral loads measured on the same sample by RT-PCR and by LAMP will be carried out.
Evaluation of the use of saliva samples compared to nasopharyngeal samples1 dayThe RT-PCR results on these 2 types of samples and the LAMP results for the saliva samples will be compared with the patient diagnosis to assess the feasibility and performance of the saliva samples for the molecular diagnosis of SARS-CoV-2.

Countries

France

Contacts

PRINCIPAL_INVESTIGATORREYNES Jacques, PU PH

Montpellier Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 13, 2026